Elaine Yang - 07 Dec 2021 Form 4 Insider Report for Zosano Pharma Corp

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 07 Dec 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Dec 2021, 17:35:28 UTC
Source filing: View source filing
Reporting owner signature: /s/ Christine Matthews, Attorney-in-fact for Elaine Yang

Key filing fact

Elaine Yang filed Form 4 for Zosano Pharma Corp on 09 Dec 2021.

Key facts

This page summarizes Elaine Yang's Form 4 filing for Zosano Pharma Corp.
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 09 Dec 2021, 17:35.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ZSAN transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +90,000
Change %
Price: $0.000000
Shares after: 90,000
Date: 07 Dec 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 90,000
Exercise price: $0.5580
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The stock option will vest with respect to 25% of the total number of the underlying shares on December 7, 2022, and the remaining shares will vest in equal monthly installments over the following three-year period such that the stock option will be fully vested on December 7, 2025